Intelligent Bio Solutions Inc. (INBS)vsJohnson & Johnson (JNJ)
INBS
Intelligent Bio Solutions Inc.
$1.97
-6.68%
HEALTHCARE · Cap: $5.50M
JNJ
Johnson & Johnson
$248.94
-1.67%
HEALTHCARE · Cap: $623.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 2462323% more annual revenue ($96.36B vs $3.91M). JNJ leads profitability with a 21.8% profit margin vs -296.8%. JNJ earns a higher WallStSmart Score of 57/100 (C).
INBS
Hold38
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-26.5%
Fair Value
$4.15
Current Price
$1.97
$2.18 premium
Margin of Safety
-85.4%
Fair Value
$136.92
Current Price
$248.94
$112.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 45.5% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -170.2% — below average capital efficiency
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : INBS
The strongest argument for INBS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.5% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : INBS
The primary concerns for INBS are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
INBS profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
INBS carries more volatility with a beta of 4.17 — expect wider price swings.
INBS is growing revenue faster at 45.5% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 38/100), backed by strong 21.8% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Intelligent Bio Solutions Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Intelligent Bio Solutions Inc. (INBS) is a cutting-edge biotechnology company focused on pioneering advanced diagnostic solutions and biomarker-driven technologies specifically designed for drug abuse testing and monitoring. By leveraging innovative scientific methodologies, INBS provides rapid and precise testing options that facilitate timely clinical decision-making and enhance patient outcomes. As the healthcare landscape increasingly demands sophisticated diagnostic tools, INBS is well-positioned to spearhead advancements in healthcare diagnostics, reaffirming its dedication to elevating healthcare quality and operational efficiency.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?